Evidence map›Paper›PMID 39000197›Full record

ArticleInternational journal of molecular sciences2024

Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing.

Sergei A Lukyanov, Sergei E Titov, Evgeniya S Kozorezova, Pavel S Demenkov, Yulia A Veryaskina, Denis V Korotovskii, Tatyana E Ilyina, Sergey L Vorobyev, Vladimir A Zhivotov, Nikita S Bondarev and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Investigation of the Anticarcinogenic Effects ofAnti-cancer agents in medicinal chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sergei A LukyanovDepartment of General and Pediatric Surgery, South Ural State Medical University, Chelyabinsk 454092, Russia.ORCID 0000-0001-5559-9872
Sergei E TitovDepartment of the Structure and Function of Chromosomes, Institute of Molecular and Cellular Biology, SB RAS, Novosibirsk 630090, Russia.ORCID 0000-0001-9401-5737
Evgeniya S KozorezovaNational Center of Clinical Morphological Diagnostics, Saint Petersburg 192283, Russia.ORCID 0000-0002-3659-7510
Pavel S DemenkovDepartment of Natural Sciences, Novosibirsk State University, Novosibirsk 630090, Russia.ORCID 0000-0001-9433-8341
Yulia A VeryaskinaDepartment of the Structure and Function of Chromosomes, Institute of Molecular and Cellular Biology, SB RAS, Novosibirsk 630090, Russia.ORCID 0000-0002-3799-9407
Denis V KorotovskiiDepartment of General and Pediatric Surgery, South Ural State Medical University, Chelyabinsk 454092, Russia.ORCID 0000-0003-2198-4793
Tatyana E IlyinaDepartment of General and Pediatric Surgery, South Ural State Medical University, Chelyabinsk 454092, Russia.
Sergey L VorobyevNational Center of Clinical Morphological Diagnostics, Saint Petersburg 192283, Russia.
Vladimir A ZhivotovDepartment of Surgery, National Medical and Surgical Center Named after N.I. Pirogov, Moscow 105203, Russia.
Nikita S BondarevDepartment of Surgery, National Medical and Surgical Center Named after N.I. Pirogov, Moscow 105203, Russia.
Ilya V SleptsovDepartment of Faculty Surgery, Saint Petersburg State University, Saint Petersburg 199034, Russia.
Sergei V SergiykoDepartment of General and Pediatric Surgery, South Ural State Medical University, Chelyabinsk 454092, Russia.

Funding

Russian Science Foundation 20-14-00074-P
6 · The paper itself

Abstract

Molecular genetic events are among the numerous factors affecting the clinical course of papillary thyroid carcinoma (PTC). Recent studies have demonstrated that aberrant expression of miRNA, as well as different thyroid-related genes, correlate with the aggressive clinical course of PTC and unfavorable treatment outcomes, which opens up new avenues for using them in the personalization of the treatment strategy for patients with PTC. In the present work, our goal was to assess the applicability of molecular markers in the preoperative diagnosis of aggressive variants of papillary thyroid cancer. The molecular genetic profile (expression levels of 34 different markers and BRAF mutations) was studied for 108 cytology specimens collected by fine-needle aspiration biopsy in patients with PTC having different clinical manifestations. Statistically significant differences with adjustment for multiple comparisons (

Indexed as

Biomarkers, TumorMicroRNAsThyroid Cancer, PapillaryThyroid NeoplasmsAdultAgedBiopsy, Fine-NeedleCyclin-Dependent Kinase Inhibitor p16FemaleFibronectinsGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationPrognosisBiomarkers, TumorBRAF protein, humanCyclin-Dependent Kinase Inhibitor p16FibronectinsFN1 protein, humanMicroRNAsProto-Oncogene Proteins B-rafaggressive variantsCDKN2AFN1miRNA-146bmiRNA-221papillary thyroid carcinomarecurrence risk

Identifiers

PMID39000197
PMCPMC11241318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.